CPT code 19083 identifies an ultrasound-guided, percutaneous breast biopsy of a single lesion and may include placement of a localization device. This procedure is a common diagnostic step for evaluating suspicious breast findings detected on imaging or clinical exam and plays an important role in cancer diagnosis and management across the United States. Accurate coding for 19083 affects claims adjudication, clinical documentation, and downstream care coordination.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of how 19083 is used in practice, the typical clinical and service settings where it occurs, and the elements that influence billing and coverage decisions. The publication provides benchmarks and context on utilization patterns, common modifier usage, and relevant policy updates where available. It also summarizes clinical considerations tied to ultrasound guidance versus other imaging modalities and notes implications for site-of-service selection and post-procedure management.

This summary is intended for billing managers, practice administrators, radiology and breast surgeons, and health policy analysts seeking a national-level overview of CPT code 19083 and its operational and reimbursement context.